With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that offers pipeline-in-a-product potential addressing a target that has clinical and regulatory validation from a recently approved Novartis drug. Vidya’s molecule is a next-generation drug that could have advantages over Novartis’s pill.
The post Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product appeared first on MedCity News.
Mythos uncovers crypto weaknesses that went unknown for years
Anthropic is hailing the results of two cryptographic problems it threw at its Mythos AI security model that found weaknesses in the mathematical problems underpinning
